Anti-PL2L60 Antibody (KAO3)
Anti-PL2L60 Antibody (KAO3) is a PL2L60-targeting antibody. Anti-PL2L60 Antibody (KAO3) binds to PL2L60 expressed on tumor cell surfaces, blocking its tumor-promoting functions. Anti-PL2L60 Antibody (KAO3) arrests tumor cell cycle and induces cancer cell apoptosis. Anti-PL2L60 Antibody (KAO3) activates complement to mediate tumor cell lysis. Anti-PL2L60 Antibody (KAO3) can be used for the research of lymphoma, breast cancer, lung cancer, cervical cancer, colon cancer, and melanoma[1].
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Species Reactivity
Human
In Vitro
Anti-PL2L60 Antibody (KAO3) (1 h) binds to PL2L60 expressed on the surface of mouse 2C4, 326T-4, human MDA-MB-231, A549, and HeLa tumor cells, with the highest binding observed on 2C4 cells[1].
Anti-PL2L60 Antibody (KAO3) (48 h) inhibits proliferation of mouse 2C4, 326T-4, human MDA-MB-231, A549, and HeLa tumor cells in a dose-dependent manner, with the strongest effect observed in 2C4 cells[1].
Anti-PL2L60 Antibody (KAO3) (48 h) induces apoptosis in mouse 2C4, 326T-4, human MDA-MB-231, A549, and HeLa tumor cells, with the largest relative increase observed in 326T-4 cells[1].
Anti-PL2L60 Antibody (KAO3) (48 h) induces G2/M phase cell cycle arrest in mouse 2C4, 326T-4, human MDA-MB-231, A549, and HeLa tumor cells, with the most profound arrest observed in 2C4 cells[1].
Anti-PL2L60 Antibody (KAO3) mediates complement-dependent cytotoxicity in mouse 2C4, 326T-4, human MDA-MB-231, A549, and HeLa tumor cells, with the strongest cytotoxicity observed in 2C4 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Anti-PL2L60 Antibody (KAO3) (intratumoral; every 2 days) significantly slows 326T-4-induced lymphoma tumor growth in SCID mice despite no effect on tumor incidence[1].
Anti-PL2L60 Antibody (KAO3) (intratumoral; every 2 days) reduces MDA-MB-231-induced breast cancer tumor incidence to 50% and significantly slows tumor growth in SCID mice[1].
Anti-PL2L60 Antibody (KAO3) (intratumoral; every 2 days) significantly slows A549-induced lung cancer tumor growth in SCID mice[1].
Anti-PL2L60 Antibody (KAO3) (intratumoral; every 2 days) moderately slows HeLa-induced cervical cancer tumor growth in SCID mice despite no effect on tumor incidence[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Target
PIWIL2-like (PL2L) protein 60/PL2L60
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Product Image
Application
ELISA, FACS, Functional assay
Chemical Information
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anti-PL2L60 Antibody (KAO3) Related Classifications
HY-P992291 Related Classifications
Powered by Bioz